| Literature DB >> 29206151 |
Flavia Castellano1,2,3, Valérie Molinier-Frenkel4,5,6.
Abstract
l-amino acid oxidases are flavin adenine dinucleotide-dependent enzymes present in all major kingdom of life, from bacteria to mammals. They participate in defense mechanisms by limiting the growth of most bacteria and parasites. A few mammalian LAAOs have been described, of which the enzyme "interleukin-4 induced gene 1" (IL4I1) is the best characterized. IL4I1 mainly oxidizes l-phenylalanine. It is a secreted enzyme physiologically produced by antigen presenting cells of the myeloid and B cell lineages and T helper type (Th) 17 cells. Important roles of IL4I1 in the fine control of the adaptive immune response in mice and humans have emerged during the last few years. Indeed, IL4I1 inhibits T cell proliferation and cytokine production and facilitates naïve CD4⁺ T-cell differentiation into regulatory T cells in vitro by limiting the capacity of T lymphocytes to respond to clonal receptor stimulation. It may also play a role in controlling the germinal center reaction for antibody production and limiting Th1 and Th17 responses. IL4I1 is expressed in tumor-associated macrophages of most human cancers and in some tumor cell types. Such expression, associated with its capacity to facilitate tumor growth by inhibiting the anti-tumor T-cell response, makes IL4I1 a new potential druggable target in the field of immunomodulation in cancer.Entities:
Keywords: ">l-amino acid oxidase; IL4I1; immunosuppression
Mesh:
Substances:
Year: 2017 PMID: 29206151 PMCID: PMC6149928 DOI: 10.3390/molecules22122151
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Reaction catabolized by . Schematic representation of the reaction catabolized by LAAOs. R = amino acid specific group.
Figure 2Regulation of T cell proliferation, functions, and differentiation by IL4I1. IL4I1 is released in the synaptic cleft from granules accumulated in mature antigen presenting cells. The enzyme binds to the surface of T cells and blocks signaling downstream of the T cell receptor (TCR). The diminished T cell activation leads to impaired proliferation and capacity to produce Th1 cytokines and proinflammatory chemokines. Moreover, naïve CD4+ T cells exposed to IL4I1 preferentially differentiate into regulatory T cells if not stimulated by strong cytokine signals. Inhibition of effector T cell activation and increased differentiation of regulatory T cells result in a state of immunosuppression.
Figure 3IL4I1 production in vivo. Left: homeostatic conditions and acute immune response. IL4I1 is detected in secondary lymphoid organs, particularly in germinal center B cells and tingible body macrophages during the development of the T-cell-dependent antibody response. The isoform 2 of IL4I1 is present in rare cells of the central nervous system (CNS). In the blood, IL4I1 is naturally produced by monocytes, dendritic cells, and T helper type 17 (Th17) cells. Right: chronic inflammatory conditions. IL4I1 is detected in Th1 inflammatory lesions including sarcoidosis and tuberculosis granuloma. A high density of IL4I1 granules is present in dendritic cells and macrophage-derived epithelioid and giant multinucleated cells. In the lung of Aspergillus fumigatus (Af)-infected individuals, IL4I1 is also produced by type II alveolar epithelial cells (AECII). In tumors, IL4I1 is secreted by infiltrating dendritic cells and macrophages, regardless of the tumor type. IL4I1 is also expressed by some tumor cell types, such as germinal center derived B-cell lymphoma (not depicted).